Literature DB >> 22443534

Pharmacokinetics and disposition of various drug loaded liposomes.

Shuai Qian1, Chenrui Li, Zhong Zuo.   

Abstract

Due to great efforts in past 45 years, several liposomal products including two liposomal vaccine products have been commercialized and many more potential products are now under clinical trial stage. Although liposome has significantly reduced the toxicity of the drugs with improved or maintained the efficacy, its further development has been limited by its instabilities during preparation and storage, incompatibility with certain drugs, relative high cost of production and quality control as well as unspecified drug release time and sites in vivo. In vivo behaviors of liposomal drugs highly depend on their physiochemical properties including lipid composition, particle size, surface charge, surface modifications and the administrated dose as well as the route of administration. Based on the literature reports from the past two decades, the current review provided an updated summary of the key factors in liposomal preparations for clinical usage and its impact on the alternation of pharmacokinetic and disposition behaviors of drugs encapsulated in the liposome formulations. Clinical applications of liposomal preparation in anti-tumor agents, anti-infective agents as well as the macromolecules have been highlighted.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22443534     DOI: 10.2174/138920012800166562

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  5 in total

1.  Ratiometric Delivery of Mitoxantrone and Berberine Co-encapsulated Liposomes to Improve Antitumor Efficiency and Decrease Cardiac Toxicity.

Authors:  Zimeng Yang; Liwen Zhao; Xue Wang; Zhonggui He; Yongjun Wang
Journal:  AAPS PharmSciTech       Date:  2021-01-13       Impact factor: 3.246

2.  The availability of drug by liposomal drug delivery : Individual kinetics and tissue distribution of encapsulated and released drug in mice after administration of PEGylated liposomal prednisolone phosphate.

Authors:  Evelien A W Smits; José A Soetekouw; Ebel H E Pieters; Coen J P Smits; Nicolette de Wijs-Rot; Herman Vromans
Journal:  Invest New Drugs       Date:  2018-12-13       Impact factor: 3.850

3.  Formulation design and evaluation of liposomal sepantronium bromide (YM155), a small-molecule survivin suppressant, based on pharmacokinetic modeling and simulation.

Authors:  Kohsuke Shakushiro; Hiroki Kawano; Mari Nakata; Aya Kita; Atsushi Maeda; Shunsuke Watanabe; Kazuhiro Sako; Naoto Oku
Journal:  Pharm Res       Date:  2014-07-18       Impact factor: 4.580

4.  Preparation, characterization and in vitro efficacy of magnetic nanoliposomes containing the artemisinin and transferrin.

Authors:  Amir Gharib; Zohreh Faezizadeh; Seyed Ali Reza Mesbah-Namin; Ramin Saravani
Journal:  Daru       Date:  2014-05-28       Impact factor: 3.117

5.  Preparation of liposomal amiodarone and investigation of its cardiomyocyte-targeting ability in cardiac radiofrequency ablation rat model.

Authors:  Ying Zhuge; Zhi-Feng Zheng; Mu-Qing Xie; Lin Li; Fang Wang; Feng Gao
Journal:  Int J Nanomedicine       Date:  2016-05-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.